stockrow
Friday 6 November 2026
Export XTLB’s income statement to Excel — free account
XTL Biopharmaceuticals Ltd.
XTLB Healthcare Biotechnology
1.55
0.16
−9.36%
Follow XTLB
Alert me
XTL Biopharmaceuticals Ltd. (XTLB) EV/Sales
As of 6 November 2026, XTL Biopharmaceuticals Ltd. (XTLB) trades at a EV/Sales of 1.0×. Over the past ten years it has ranged from −1.1× (March 2020) to 60.5× (February 2015); the current reading is higher than 9% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 4.8× | — |
Against its own ten years
Low −1.1×
High 60.5×
Ten-year median
3.2×
Current reading's percentile
8
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTGN VistaGen Therapeutics, Inc. compare | −6.4× |
| SNGX Soligenix Inc. compare | −4.1× |
| MTVA MetaVia Inc. compare | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| BCLI Brainstorm Cell Therapeutics Inc. compare | n/m |
| XTLB XTL Biopharmaceuticals Ltd. | 1.0× |
| ENSC Ensysce Biosciences, Inc. compare | 1.0× |
| TPST Tempest Therapeutics, Inc. compare | 22.4× |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | 25.3× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)